ARV-027 — Initial data
2H26
– Initiated dosing with ARV-027 (polyQ-AR degrader) in Phase 1 healthy volunteer trial with single-ascending dose data anticipated in 2H26 –Source filing
ARVN biotech catalysts & pipeline
ARVINAS INC · Data as of 2026-09-08
Upcoming catalysts
ARV-393 — Topline data
2H 2026
Share data from early monotherapy cohorts in the ongoing Phase 1 dose escalation clinical trial in patients with relapsed/refractory NHL (ClinicalTrials.gov Identifier: NCT06393738) at a medical congress (2H 2026).Source filing
ARV-806 — Topline data
H2 2026
Reiterated plan to share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026.Source filing
ARV-027 — Topline data
1H 2027
Continue enrollment in the multiple dose cohort of the Phase 1 clinical trial in healthy volunteers and share initial data evaluating androgen receptor (AR)-degradation in muscle (1H 2027).Source filing
ARV-393 — Topline data
mid-2027
Share data from the combination cohort with glofitamab in patients with DLBCL in the ongoing Phase 1 clinical trial (mid-2027).Source filing
ARV-102 — Conference presentation
Oct 4–Oct 8
Share additional biomarker data from the Phase 1 clinical trial in patients with Parkinson's disease at the International Congress on Parkinson's Disease and Movement Disorders (October 2026).Source filing